Abstract:
To the Editor: The cyclo-oxygenase-2 (COX-2) inhibitors and
other non-steroidal anti-inflammatory drugs (NSAIDs) have
been the subject of scrutiny generated mainly by evidence
suggesting that rofecoxib is associated with increased
cardiovascular risk. Chin and Commerford1 have summarised
some of the large volume of data; however, a critical review of
published work yields interesting insights.
